Thermo Fisher Scientific (TMO) Reports In-Line Q3 EPS; Cuts FY11 Outlook
Tweet
Share
E-mailGet Alerts TMO Hot Sheet
Price: $603.01 --0%
Financial Fact:
Selling, general and administrative expenses: 1.27B
Today's EPS Names:
VAXX, NMRD, EGRX, More
Financial Fact:
Selling, general and administrative expenses: 1.27B
Today's EPS Names:
VAXX, NMRD, EGRX, More
Join SI Premium – FREE
Thermo Fisher Scientific (NYSE: TMO) reported Q3 EPS of $1.07, in-line with the analyst estimate of $1.07. Revenue for the quarter came in at $2.97 billion versus the consensus estimate of $3 billion.
Thermo Fisher Scientific sees FY2011 EPS of $4.11-$4.17, versus prior guidance of $4.15-$4.25 and the consensus of $4.20. Sees FY2011 revenue of $11.62-$11.70 billion, versus prior guidance of $11.79-$11.89 billion and the consensus of $11.83 billion.
Thermo Fisher Scientific sees FY2011 EPS of $4.11-$4.17, versus prior guidance of $4.15-$4.25 and the consensus of $4.20. Sees FY2011 revenue of $11.62-$11.70 billion, versus prior guidance of $11.79-$11.89 billion and the consensus of $11.83 billion.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ondas Holdings Inc. (ONDS) Misses Q2 EPS by 9c
- Rekor Systems, Inc. (REKR) Tops Q2 EPS by 3c
- Karyopharm Therapeutics (KPTI) Misses Q2 EPS by $1.01, Beats on Revenue; Offers FY26 Revenue Guidance
Create E-mail Alert Related Categories
Earnings, Guidance, Hot GuidanceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
